DEFA14A ·Filed Apr 24, 2026

SVRA

Savara Inc
NEUTRAL
Impact 3/10
Horizonimmediate Processed5mo ago SEC0001193125-26-177360
Proxy solicitation materials
Actionable Insight • Neutral

Monitor the voting results for the share increase and incentive plan amendments, as these could significantly impact future shareholder dilution and executive incentives.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
SVRA ▲ +9.50% at T+60d
NEUTRAL call ✓ call won +9.50% · α vs SPY +4.72% · entry $5.16 → $5.65
Entry anchored
Apr 24, 03:59 PM ET
via exchange tick
T+1d
-2.71%
call -2.71% · α -2.23%
$5.02
settled 5mo ago
T+5d
+2.71%
call +2.71% · α +2.31%
$5.30
settled 5mo ago
T+20d
-0.39%
call -0.39% · α -5.34%
$5.14
settled 4mo ago
T+60d
+9.50%
call +9.50% · α +4.72%
$5.65
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

Savara Inc. is holding its 2026 Annual Meeting of Stockholders, where shareholders are being asked to vote on several key proposals, including the election of six directors, an increase in authorized shares, an amendment to the Omnibus Incentive Plan, ratification of the independent auditor, and approval of executive compensation.

Key Facts

  • Savara Inc. is holding its 2026 Annual Meeting of Stockholders.
  • Shareholders are being asked to vote on the election of six directors.
  • Shareholders are being asked to vote on an amendment to increase the number of authorized shares of common stock from 300,000,000 to 600,000,000.
  • Shareholders are being asked to vote on an amendment to the Savara Inc. 2024 Omnibus Incentive Plan to increase the number of shares authorized for issuance by 18,900,000.
  • Shareholders are being asked to vote on the ratification of RSM US LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
  • Shareholders are being asked to vote on the approval, on an advisory basis, of the compensation of the named executives.

Financial Impact

The proposed share increase would double the company's authorized shares, and the incentive plan amendment would add 18.9 million shares for issuance.

authorized sharesdilutionexecutive compensation

Risk Factors

  • The increase in authorized shares could lead to significant future dilution if the company issues a large portion of the new shares.
  • The amendment to the incentive plan could increase shareholder dilution and affect executive compensation practices.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-177360
Document: 0001193125-26-177360-index-headers.html0001193125-26-177360
Document: 0001193125-26-177360-index.html0001193125-26-177360
Document: 0001193125-26-177360.txt0001193125-26-177360
3 reports for SVRA
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for SVRA — sortable, filterable
TypeNow
Aug 9, 2026
7w ago
Institutional Cluster
BULLISH ★ 5/10
$5.73 $5.53▼ −3.49%▼ −2.58%$4.78 (−16.67%)
Jun 11, 2026
16w ago
Institutional Cluster
MIXED ★ 4/10
$5.26 $6.03▲ +14.64%▲ +12.86%$4.78 (−9.22%)
Apr 24, 2026
22w ago
DEFA14A
NEUTRAL ★ 3/10
$5.16 $5.14▼ −0.39%▼ −5.34%$4.78 (−7.46%)
Showing 3 of 3

US Market Status

Market Open — Closes in 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access